Juliette Berangere Audet - 01 Apr 2024 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: Chief Business Officer
Signature: /s/ Louise Kooij by Power of Attorney from Juliette Berangere Audet
Issuer symbol: NAMS
Transactions as of: 01 Apr 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Apr 2024, 16:30:15 UTC
Previous filing: 29 Dec 2023
Next filing: 30 Sep 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAMS	Option (right to buy)	Award	$0	+250,000		$0.000000	250,000	01 Apr 2024	Ordinary Shares	250,000	$21.37	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person resigned from the Issuer's board of directors, effective April 1, 2024, in light of her appointment as the Issuer's Chief Business Officer ("CBO"). The option reported herein was granted in connection with the Reporting Person's appointment as CBO.
F2	25% of the shares underlying the option will vest on April 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.